TAK-007

Unassigned

New Medicines

Refractory or relapsing CD 19 positive B-lymphoid malignancies (ALL, CLL, NHL) following at least 2 lines of chemoimmunotherapy, targeted therapy and stem cell transplant

Information

Advanced therapy medicinal product (ATMP)
Takeda
Takeda

Development and Regulatory status

None
None
Phase II Clinical Trials

Category

Cord blood derived (allogeneic) CD19 CAR Natural Killer (NK) cells modified with retroviral vector to express IL-15. A CD19 CAR increases specificity for B-cell malignancies whilst IL-15 enhances proliferation and survival of CAR NK cells in vivo. [1]
There were 13,886 new cases of NHL in 2014-2016 average in the UK and 3789 cases of CLL in the same period. Around 3,800 people are diagnosed with CLL in the UK each year.[2]
Refractory or relapsing CD 19 positive B-lymphoid malignancies (ALL, CLL, NHL) following at least 2 lines of chemoimmunotherapy, targeted therapy and stem cell transplant
Intravenous infusion